Article Details
Retrieved on: 2021-05-12 22:41:15
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
... an anti-CD52 monoclonal antibody, to be used as part of a lymphodepleting regimen in certain Cellectis-sponsored UCART clinical trials. Sanofi will ...
Article found on: www.bioworld.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here